Human TRAIL/TNFSF10 Antibody | R&D Systems MAB375 product information

This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.

product summary

company name :

R&D Systems

product type :

antibody

product name :

Human TRAIL/TNFSF10 Antibody

catalog :

MAB375

quantity :

100 ug (also 25 ug, 500 ug)

price :

359 USD

clonality :

monoclonal

host :

mouse

conjugate :

nonconjugated

clone name :

75411

reactivity :

human

application :

immunohistochemistry, neutralization, blocking or activating experiments

citations: 13

Published Application/Species/Sample/Dilution	Reference
blocking or activating experiments; human; 100 ng/ml; loading ...; fig s7b	Vickman R, Yang J, Lanman N, Cresswell G, Zheng F, Zhang C, et al. Cholesterol Sulfotransferase SULT2B1b Modulates Sensitivity to Death Receptor Ligand TNFα in Castration-Resistant Prostate Cancer. Mol Cancer Res. 2019;17:1253-1263 pubmed publisher
blocking or activating experiments; human; loading ...; fig s2	Tanzer M, Khan N, Rickard J, Etemadi N, Lalaoui N, Spall S, et al. Combination of IAP antagonist and IFNÎ³ activates novel caspase-10- and RIPK1-dependent cell death pathways. Cell Death Differ. 2017;24:481-491 pubmed publisher
	Jørgensen M, Bæk R, Sloth J, Varming K, Christiansen O, Ditlevsen N, et al. Treatment with intravenous immunoglobulin increases the level of small EVs in plasma of pregnant women with recurrent pregnancy loss. J Reprod Immunol. 2020;140:103128 pubmed publisher
	Arnold N, Pickworth J, West L, Dawson S, Carvalho J, Casbolt H, et al. A therapeutic antibody targeting osteoprotegerin attenuates severe experimental pulmonary arterial hypertension. Nat Commun. 2019;10:5183 pubmed publisher
	Radke D, Ungefroren H, Helm O, Voigt S, Alp G, Braun H, et al. Negative control of TRAIL-R1 signaling by transforming growth factor ?1 in pancreatic tumor cells involves Smad-dependent down regulation of TRAIL-R1. Cell Signal. 2016;28:1652-62 pubmed publisher
	Tel J, Smits E, Anguille S, Joshi R, Figdor C, de Vries I. Human plasmacytoid dendritic cells are equipped with antigen-presenting and tumoricidal capacities. Blood. 2012;120:3936-44 pubmed publisher
	Kalb M, Glaser A, Stary G, Koszik F, Stingl G. TRAIL(+) human plasmacytoid dendritic cells kill tumor cells in vitro: mechanisms of imiquimod- and IFN-?-mediated antitumor reactivity. J Immunol. 2012;188:1583-91 pubmed publisher
	Inglefield J, Dumitru C, Alkan S, Gibson S, Lipson K, Tomai M, et al. TLR7 agonist 852A inhibition of tumor cell proliferation is dependent on plasmacytoid dendritic cells and type I IFN. J Interferon Cytokine Res. 2008;28:253-63 pubmed publisher
	Kavurma M, Schoppet M, Bobryshev Y, Khachigian L, Bennett M. TRAIL stimulates proliferation of vascular smooth muscle cells via activation of NF-kappaB and induction of insulin-like growth factor-1 receptor. J Biol Chem. 2008;283:7754-62 pubmed publisher
	Krysov S, Rowley T, Al Shamkhani A. Inhibition of p38 mitogen-activated protein kinase unmasks a CD30-triggered apoptotic pathway in anaplastic large cell lymphoma cells. Mol Cancer Ther. 2007;6:703-11 pubmed
	Georgopoulos N, Steele L, Thomson M, Selby P, Southgate J, Trejdosiewicz L. A novel mechanism of CD40-induced apoptosis of carcinoma cells involving TRAF3 and JNK/AP-1 activation. Cell Death Differ. 2006;13:1789-801 pubmed
	Brando C, Mukhopadhyay S, Kovacs E, Medina R, Patel P, Catina T, et al. Receptors and lytic mediators regulating anti-tumor activity by the leukemic killer T cell line TALL-104. J Leukoc Biol. 2005;78:359-71 pubmed
	Armeanu S, Lauer U, Smirnow I, Schenk M, Weiss T, Gregor M, et al. Adenoviral gene transfer of tumor necrosis factor-related apoptosis-inducing ligand overcomes an impaired response of hepatoma cells but causes severe apoptosis in primary human hepatocytes. Cancer Res. 2003;63:2369-72 pubmed

product information

brand :

R&D Systems

master code :

MAB375

SKU :

MAB375-100

product name :

Human TRAIL/TNFSF10 Antibody

description :

The Human TRAIL/TNFSF10 Antibody from R&D Systems is a mouse monoclonal antibody to TRAIL/TNFSF10. This antibody reacts with human. The Human TRAIL/TNFSF10 Antibody has been validated for the following applications: Immunohistochemistry, Neutralization.

target :

TRAIL/TNFSF10

category :

Primary Antibodies

unit size :

100 ug (also 25 ug, 500 ug)

buffer :

Lyophilized from a 0.2 µm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 µm filtered solution in PBS.

clonality :

Monoclonal

clone :

75411

conjugate :

Unconjugated

host :

Mouse

immunogen :

Mouse myeloma cell line NS0-derived recombinant human TRAIL/TNFSF10, Thr95-Gly281, Accession # P50591

isotype :

IgG1

purity :

Protein A or G purified from ascites

species :

Human

specificity :

Detects human TRAIL/TNFSF10 in direct ELISAs.

gene symbol :

TNFSF10

endotoxin note :

<0.10 EU per 1 µg of the antibody by the LAL method.

catalog number base :

MAB375

accessionNumbers :

P50591

applications :

Immunohistochemistry, Neutralization

2020 USD :

339

2021 USD :

359 USD

alt names :

Apo-2 ligand, APO2L, Apo-2Ltumor necrosis factor (ligand) family, member 10, APO2Ltumor necrosis factor apoptosis-inducing ligand splice variant delta, CD253, CD253 antigen, Protein TRAIL, TL2, TNF-related apoptosis-inducing ligand, TNFSF10, TRAILTNF-related apoptosis inducing ligand TRAIL, tumor necrosis factor (ligand) superfamily, member 10, tumor necrosis factor ligand superfamily member 10

storage :

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 6 months, -20 to -70 °C under sterile conditions after reconstitution.